GlassScriptPhysician profile
William Isaac Feingold
NPI 1417392846
$3,173.17
in general payments reported to CMS, 2019-2025
20 companies · $1,163 in 2025
The $1,163 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $76.25 · 2021: $19.44 · 2022: $415 · 2023: $448 · 2024: $613 · 2025: $1,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $884.92 | 2025 | Rapiblyk |
| Janssen Pharmaceuticals, INC | $340.53 | 2019-2024 | Xarelto |
| Vifor Pharma, INC. | $245.00 | 2019-2023 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $192.04 | 2019-2023 | Lokelma |
| Alexion Pharmaceuticals, INC. | $187.45 | 2022-2025 | Ultomiris, Soliris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.41 | 2019-2025 | Xifaxan |
| Pfizer INC. | $170.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $154.21 | 2022-2025 | Eliquis |
| Shionogi INC | $135.99 | 2022-2024 | Fetroja |
| Merck Sharp & Dohme LLC | $101.70 | 2019-2024 | Verquvo, Dificid, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.22 | 2019-2025 | Jardiance |
| Ferring Pharmaceuticals INC. | $94.11 | 2023-2025 | Rebyota |
| Abbvie INC. | $88.45 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $64.24 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $60.10 | 2024 | Nuzyra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $59.22 | 2019 | |
| Csl Behring | $51.36 | 2019-2024 | Kcentra |
| Melinta Therapeutics, LLC | $32.75 | 2024-2025 | Rezzayo, Kimyrsa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.05 | 2025 | Lifevest |
| Cumberland Pharmaceuticals, INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Feingold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.